Pharmacodynamics

Quick Answer

Pharmacodynamics is the study of the biochemical and physiological effects of drugs and their mechanisms of action, specifically examining the interaction between drugs and biological systems to produce therapeutic or toxic effects. Drug-receptor interactions represent the fundamental basis of pharmacodynamics, with receptors being specific macromolecules (typically proteins including enzymes, ion channels, transporters, or transcription factors) that recognize and respond to endogenous ligands or exogenous drugs. Agonists are molecules that bind to receptors and activate them, producing a biological response, while antagonists bind to receptors without activating them, thereby blocking the action of agonists. Full agonists produce maximum possible receptor activation, partial agonists produce submaximal activation even at complete receptor occupancy, and inverse agonists actively reduce basal receptor activity below baseline levels. Efficacy (intrinsic activity) describes the maximum biological response a drug can produce, independent of potency, while potency reflects the drug concentration required to produce a specified effect, typically expressed as EC50 (concentration producing 50% of maximum response). The relationship between drug concentration and effect follows a sigmoid Emax model: E = (Emax × Cⁿ) / (EC50ⁿ + Cⁿ), where n represents the Hill coefficient reflecting receptor cooperativity. Understanding these pharmacodynamic principles is essential for rational drug selection, predicting drug interactions, managing tolerance and tachyphylaxis, and optimizing anaesthetic drug combinations in clinical practice. [1-12]

Drug-Receptor Interactions

Receptor Theory Fundamentals

The concept of receptors as specific drug recognition sites originated with Langley (1878) and Ehrlich (1900), establishing that drugs exert effects by interacting with discrete molecular targets rather than through nonspecific actions. Modern receptor theory, developed by Clark, Ariëns, and Stephenson, provides the quantitative framework for understanding drug-receptor interactions. [13-20]

Receptors possess three fundamental properties:

Recognition: Specific structural features (binding sites) that recognize and bind ligands
Transduction: Mechanisms to convert ligand binding into cellular responses
Amplification: Systems to magnify the initial signal through second messenger cascades

[21-28]

The law of mass action governs drug-receptor binding: as drug concentration increases, the proportion of receptors occupied increases according to the binding equation: [DR] = ([D] × [R_total]) / ([D] + Kd), where [DR] is drug-receptor complex concentration, [D] is free drug concentration, [R_total] is total receptor concentration, and Kd is the dissociation constant (drug concentration occupying 50% of receptors). [29-36]

Receptor Types in Anaesthetic Pharmacology

Ligand-gated ion channels (ionotropic receptors): Transmembrane proteins that form ion channels opening in response to ligand binding. Examples include:

GABA_A receptors: Target for propofol, benzodiazepines, barbiturates, etomidate
Nicotinic acetylcholine receptors: Target for neuromuscular blocking agents
NMDA receptors: Target for ketamine, nitrous oxide
Glycine receptors: Target for propofol, some muscle relaxants

[37-48]

G-protein coupled receptors (GPCRs, metabotropic receptors): Seven-transmembrane domain receptors that activate intracellular G-proteins. Examples include:

Opioid receptors (μ, δ, κ): Morphine, fentanyl, remifentanil
Adrenergic receptors (α1, α2, β1, β2): Phenylephrine, clonidine, beta-blockers
Muscarinic acetylcholine receptors: Atropine, glycopyrrolate
Cannabinoid receptors: Endocannabinoid system modulation

[49-60]

Enzyme-linked receptors: Receptors with intrinsic enzymatic activity or associated enzymes. Examples include:

Receptor tyrosine kinases: Growth factor signaling
Janus kinase (JAK)-associated receptors: Cytokine signaling, relevant to inflammation

[61-66]

Intracellular receptors: Nuclear receptors that regulate gene transcription. Examples include:

Glucocorticoid receptors: Dexamethasone, methylprednisolone
Thyroid hormone receptors: Relevant to metabolic rate
Sex hormone receptors: Relevant to drug metabolism differences

[67-74]

Spare Receptors and Receptor Reserve

Spare receptors (receptor reserve) describe the phenomenon where maximum biological response can be achieved without occupying all available receptors. This concept explains why some agonists produce full effects at receptor occupancies significantly less than 100%. [75-82]

The clinical significance of spare receptors includes:

Enhanced sensitivity to agonists in tissues with high receptor reserve
Preservation of drug effects despite receptor loss or downregulation
Amplification of weak agonist signals through signal transduction cascades
Tissue-selective effects based on differential receptor reserve

[83-90]

Tissues with high receptor reserve (e.g., cardiac β1-adrenergic receptors) may maintain nearly normal responses despite substantial receptor loss, while tissues with low receptor reserve show proportionally reduced responses. This concept is relevant to understanding tolerance mechanisms and the effects of receptor antagonists in different tissues. [91-98]

Agonists

Full Agonists

Full agonists are ligands that bind to receptors and produce the maximum possible biological response that the receptor system can generate. At sufficient concentrations, full agonists can achieve complete receptor occupancy and elicit the full tissue response. [99-106]

Characteristics of full agonists:

High intrinsic efficacy (α = 1.0, where α represents the proportion of activated receptors producing response)
Can overcome the effects of competitive antagonists at sufficient concentrations
Produce identical maximum responses regardless of absolute potency differences
Examples: Morphine (μ-opioid), isoprenaline (β-adrenergic), propofol (GABA_A at high concentrations)

[107-116]

The concept of intrinsic efficacy, developed by Stephenson, distinguishes between affinity (binding strength) and efficacy (ability to activate). Two drugs may have identical receptor affinities but markedly different efficacies, producing different maximum responses. [117-124]

Partial Agonists

Partial agonists bind to receptors and produce a submaximal response even when all receptors are occupied. They possess intermediate intrinsic efficacy (0 < α < 1.0) and cannot produce the same maximum response as full agonists, regardless of concentration. [125-132]

Clinically relevant partial agonists in anaesthesia:

Buprenorphine: Partial agonist at μ-opioid receptors (ceiling effect on respiratory depression at ~30 mcg IV, but analgesic ceiling at higher doses)
Nalbuphine, pentazocine: Mixed agonist-antagonists with partial agonist activity
Pindolol: Partial β-adrenergic agonist
Clonidine: Partial α2-agonist compared to dexmedetomidine

[133-144]

Partial agonists exhibit complex interactions with full agonists:

In the absence of full agonists, partial agonists produce submaximal responses
In the presence of full agonists, partial agonists may act as antagonists, reducing the full agonist response toward the partial agonist's ceiling
This dual agonist-antagonist property makes partial agonists useful for maintaining moderate effects while limiting toxicity (e.g., buprenorphine for opioid maintenance therapy)

[145-156]

Inverse Agonists

Inverse agonists bind to receptors and actively reduce basal receptor activity below the level observed in the absence of ligand. They stabilize the inactive conformation of receptors that exhibit constitutive (basal) activity. [157-164]

Inverse agonists differ from simple antagonists:

Neutral antagonists: Block both agonist and inverse agonist effects, returning activity to basal level
Inverse agonists: Reduce activity below basal level by preferentially binding to inactive receptor conformation
Clinically relevant examples include some antihistamines (H1 inverse agonists) and certain beta-blockers at constitutively active β-adrenergic receptors

[165-174]

Antagonists

Competitive Antagonists

Competitive antagonists bind reversibly to the same receptor site as agonists (orthosteric binding) without activating the receptor. They compete with agonists for receptor occupancy, and their effects can be overcome by increasing agonist concentration. [175-184]

Characteristics of competitive antagonism:

Parallel rightward shift in agonist concentration-response curves
Unchanged maximum response (Emax) when sufficient agonist is applied
Schild plot analysis yields pA2 value (antagonist concentration producing 2-fold shift in agonist EC50)
Antagonism is surmountable

[185-196]

Clinically relevant competitive antagonists:

Naloxone: Competitive opioid antagonist at all opioid receptor types; used for opioid overdose
Flumazenil: Competitive benzodiazepine antagonist at GABA_A receptor benzodiazepine binding site
Atropine/glycopyrrolate: Competitive muscarinic antagonists
Phenylephrine competition: Phenylephrine (α1-agonist) effects blocked by phentolamine (competitive α-antagonist)

[197-208]

The dissociation constant of competitive antagonists (Kb or Ki) quantifies affinity. The relationship is described by: EC50(antagonist) = EC50(control) × (1 + [B]/Kb), where [B] is antagonist concentration. This equation predicts the degree of rightward shift produced by a given antagonist concentration. [209-218]

Non-Competitive Antagonists

Non-competitive antagonists reduce the maximum response (Emax) of agonists without necessarily affecting potency (EC50). They may act through several mechanisms: [219-228]

Irreversible antagonists: Covalently bind to receptors, permanently inactivating them. The effect cannot be overcome by increasing agonist concentration. Examples include phenoxybenzamine (irreversible α-antagonist) and some organophosphates (irreversible cholinesterase inhibitors). [229-236]

Allosteric antagonists: Bind to regulatory sites distinct from the agonist binding site (allosteric sites), altering receptor conformation and reducing agonist efficacy without competing for the orthosteric site. Examples include some GABA_A modulators and certain opioid allosteric modulators. [237-246]

Functional antagonists: Act downstream from receptors to oppose agonist effects. Examples include drugs that counteract physiological effects without receptor interaction (e.g., antidotes for drug toxicity). [247-254]

Characteristics of non-competitive antagonism:

Depression of maximum agonist response (reduced Emax)
May or may not alter agonist EC50 depending on mechanism
Antagonism is insurmountable (cannot be overcome by increasing agonist concentration)
Schild plot analysis shows deviation from linearity

[255-264]

Uncompetitive Antagonists

Uncompetitive antagonists bind only to the agonist-receptor complex (not to free receptors), selectively blocking activated receptors. This produces unique effects on concentration-response curves: [265-272]

Leftward shift of agonist EC50 (apparent increased potency)
Reduction in maximum response at high antagonist concentrations
Effect depends on agonist concentration (more antagonism at higher agonist concentrations)
Examples include some NMDA receptor antagonists (memantine) and certain channel blockers

[273-282]

Physiological (Functional) Antagonism

Physiological antagonism occurs when two drugs produce opposite effects through different receptor mechanisms. Unlike pharmacological antagonism where both drugs act on the same receptor system, physiological antagonists counteract each other's effects through independent pathways. [283-292]

Examples in anaesthesia:

Histamine vs adrenaline: Histamine causes bronchoconstriction (H1 receptors) while adrenaline causes bronchodilation (β2 receptors)
Insulin vs glucagon: Opposite effects on blood glucose through distinct mechanisms
Vasodilators vs vasoconstrictors: Produce opposite vascular effects through different receptor pathways

[293-302]

Efficacy vs Potency

Definitions and Distinctions

Efficacy (Intrinsic Activity): The maximum biological response a drug can produce, representing the drug's ability to activate the receptor-effector system. Efficacy is independent of drug concentration or affinity and reflects the magnitude of the drug's effect when all receptors are occupied. [303-312]

Potency: The drug concentration (or dose) required to produce a specified effect, typically expressed as EC50 (concentration producing 50% of maximum response) or ED50 (dose producing 50% of maximum response). Potency reflects the strength of drug-receptor binding (affinity) and the efficiency of receptor activation. [313-322]

The distinction is crucial for clinical drug selection:

High efficacy drugs can produce maximum therapeutic effects even if less potent
High potency drugs produce effects at lower concentrations but may not achieve greater maximum effects
A drug with lower potency but higher efficacy may be preferred when maximum effects are needed
A highly potent drug with lower efficacy may be preferred when moderate effects with fewer side effects are desired

[323-336]

Quantification Methods

Efficacy quantification:

Emax: Maximum response achievable
Intrinsic activity (α): Ratio of drug Emax to reference full agonist Emax (α = 1.0 for full agonists, 0 < α < 1.0 for partial agonists)
Relative efficacy: Comparison to standard agonist

[337-346]

Potency quantification:

EC50: Concentration producing 50% of maximum response
pD2: Negative logarithm of EC50 (higher pD2 = higher potency)
ED50: Dose producing 50% of maximum response (in vivo)
Kd: Dissociation constant for receptor binding (concentration occupying 50% of receptors)

[347-356]

Drug Comparison	Relative Potency	Relative Efficacy	Clinical Implication
Fentanyl vs morphine	Fentanyl 50-100× more potent	Both full agonists, similar efficacy	Fentanyl used when rapid onset and high potency desired
Buprenorphine vs morphine	Buprenorphine more potent binding	Buprenorphine partial agonist, lower efficacy	Ceiling effect limits respiratory depression but also maximal analgesia
Dexmedetomidine vs clonidine	Dexmedetomididne more potent (α2)	Dexmedetomididine full agonist, clonidine partial	Dexmedetomididine provides more predictable sedation
Etomidate vs propofol	Similar potency at GABA_A	Both full agonists, similar efficacy	Selection based on other pharmacological properties

Table: Examples of potency and efficacy comparisons in anaesthetic drugs. [357-370]

Clinical Significance

Understanding efficacy-potency relationships guides rational drug selection:

Maximal effect scenarios: When complete receptor activation is required (e.g., profound neuromuscular blockade, complete unconsciousness), full agonists are necessary regardless of potency considerations. [371-378]

Ceiling effect considerations: Partial agonists provide safety advantages through ceiling effects (e.g., buprenorphine's respiratory depression ceiling), but their efficacy limitations must be recognized when complete receptor activation is therapeutic. [379-386]

Drug interaction predictions: Competitive antagonists reduce apparent potency (rightward EC50 shift) but not efficacy, while non-competitive antagonists reduce efficacy (lower Emax). Understanding these mechanisms predicts interaction outcomes. [387-396]

Tolerance mechanisms: Chronic agonist exposure may reduce efficacy through receptor downregulation or desensitization, requiring dose escalation or drug rotation to maintain effect. [397-406]

Concentration-Response Relationships

Sigmoid Emax Model (Hill Equation)

The relationship between drug concentration and effect is described by the sigmoid Emax model (Hill equation): [407-416]

E = (Emax × Cⁿ) / (EC50ⁿ + Cⁿ)

Where:

E = observed effect at concentration C
Emax = maximum possible effect
EC50 = concentration producing 50% of maximum effect
n = Hill coefficient (slope factor, reflects receptor cooperativity)
C = drug concentration

[417-428]

The Hill coefficient (n) describes the slope of the concentration-response curve:

n = 1: Simple Michaelis-Menten kinetics, single binding site
n > 1: Positive cooperativity, steeper curve, multiple binding sites with interaction
n < 1: Negative cooperativity, flatter curve

[429-438]

The sigmoid shape reflects:

Threshold region: Low concentrations produce minimal effects (spare receptors not yet activated)
Steep region: Small concentration changes produce large effect changes (therapeutic window)
Plateau region: High concentrations approach maximum effect (receptor saturation)

[439-448]

Quantal Dose-Response Relationships

Quantal (all-or-none) dose-response curves describe the proportion of a population exhibiting a specified effect at each dose level. Unlike graded responses where effect magnitude varies continuously, quantal responses categorize individuals as responders or non-responders. [449-458]

Key parameters from quantal dose-response curves:

ED50: Dose producing the specified effect in 50% of the population
TD50: Dose producing toxic effects in 50% of the population
LD50: Dose producing death in 50% of the population
Therapeutic index: TD50/ED50 or LD50/ED50, reflecting safety margin

[459-470]

Individual variation in drug response creates a sigmoid population dose-response curve. The steepness of this curve reflects population homogeneity—steeper curves indicate more uniform responses, while flatter curves indicate greater interindividual variability. [471-480]

Therapeutic Index and Safety Margins

The therapeutic index quantifies drug safety by comparing effective and toxic doses: [481-490]

Therapeutic Index (TI) = TD50 / ED50

A higher therapeutic index indicates greater safety (toxic dose far exceeds effective dose). Drugs with narrow therapeutic indices require careful monitoring and individualized dosing.

Drug	Therapeutic Index	Clinical Implication
Digoxin	~2-3	Narrow TI; requires TDM
Lithium	~3-4	Narrow TI; requires TDM
Theophylline	~4-5	Moderate TI; TDM recommended
Morphine	~70-300	Wide TI; respiratory depression far from analgesic dose
Propofol	>100	Very wide TI; cardiovascular collapse at high doses
Remifentanil	~100-300	Wide TI; rapid offset contributes to safety

Table: Therapeutic indices for representative drugs. [491-502]

Certain safety factor: The difference between ED99 (dose effective in 99%) and LD1 (dose lethal in 1%): Certain safety factor = LD1 / ED99. This more conservative measure accounts for tail of distribution. [503-512]

Concentration-Effect Hysteresis

Hysteresis describes the phenomenon where effect lags behind plasma concentration changes, creating a loop when effect is plotted against concentration during both increasing and decreasing phases. [513-522]

Causes of hysteresis:

Distribution delay: Time for drug to reach effect site (biophase) from plasma
Indirect effects: Time for drug to trigger downstream physiological responses
Active metabolites: Delayed formation of active compounds from prodrugs
Receptor dynamics: Time for receptor activation/desensitization

[523-534]

Effect-site modeling: To account for hysteresis, pharmacokinetic-pharmacodynamic (PK-PD) models incorporate an effect compartment with its own rate constant (ke0) describing equilibration between plasma and effect site. This allows prediction of effect timing rather than relying solely on plasma concentrations. [535-546]

Drug	ke0 (min⁻¹)	t½ke0 (min)	Clinical Implication
Fentanyl	0.105	6.6	Onset ~5-7 min; hysteresis evident
Alfentanil	0.63	1.1	Faster onset than fentanyl; less hysteresis
Remifentanil	0.95	0.73	Very rapid onset; minimal hysteresis
Propofol	0.456	1.5	Rapid onset; moderate hysteresis

Table: Effect-site equilibration rate constants for intravenous anesthetics. [547-556]

Signal Transduction Mechanisms

G-Protein Coupled Receptor Pathways

GPCRs represent the largest class of drug targets, with approximately 35% of all marketed drugs acting through these receptors. They transduce signals through heterotrimeric G-proteins (α, β, γ subunits) that modulate intracellular second messengers. [557-568]

G-protein classifications and effector mechanisms:

Gs (stimulatory): Activates adenylyl cyclase → increased cAMP → protein kinase A (PKA) activation → phosphorylation of target proteins

β-adrenergic receptors: Cardiac stimulation, bronchodilation
Dopamine D1 receptors: Vasodilation, natriuresis
Glucagon receptors: Glycogenolysis

[569-580]

Gi (inhibitory): Inhibits adenylyl cyclase → decreased cAMP; activates K+ channels; inhibits Ca2+ channels

μ, δ, κ opioid receptors: Analgesia, sedation, respiratory depression
α2-adrenergic receptors: Sedation, analgesia, sympatholysis
Muscarinic M2 receptors: Bradycardia, decreased contractility

[581-592]

Gq/11: Activates phospholipase C → IP3 and DAG formation → Ca2+ release and PKC activation

α1-adrenergic receptors: Vasoconstriction
Muscarinic M1, M3 receptors: Secretion, contraction
Angiotensin II receptors: Vasoconstriction, aldosterone release

[593-604]

G12/13: Activates RhoGEF → Rho kinase → cytoskeletal regulation

Involved in cell migration and proliferation

[605-612]

Ion Channel Receptor Mechanisms

Ligand-gated ion channels (ionotropic receptors) mediate rapid synaptic transmission by directly coupling ligand binding to ion channel opening. [613-622]

GABA_A receptor structure and function:

Pentameric structure (α, β, γ subunit combinations)
GABA binding site at α-β interface
Benzodiazepine binding site at α-γ interface
Chloride channel pore formed by M2 transmembrane domains
Positive allosteric modulators (benzodiazepines, propofol, etomidate, barbiturates) increase chloride conductance

[623-636]

Nicotinic acetylcholine receptor:

Pentameric structure (α2βγδ in muscle, α4β2 or α7 in neuronal)
Acetylcholine binding at α subunit interfaces
Cation channel (Na+, K+, Ca2+ permeable)
Depolarizing neuromuscular blockers (succinylcholine) act as agonists causing sustained depolarization
Non-depolarizing blockers (rocuronium, vecuronium) act as competitive antagonists

[637-650]

NMDA receptor:

Heterotetrameric structure requiring glycine and glutamate co-agonism
Voltage-dependent Mg2+ block
High Ca2+ permeability
Ketamine and nitrous oxide act as non-competitive antagonists at phencyclidine binding site

[651-662]

Enzyme-Linked Receptor Pathways

Enzyme-linked receptors include receptor tyrosine kinases, receptor serine/threonine kinases, and receptor guanylyl cyclases. While less common as direct anaesthetic targets, they mediate effects of drugs modulating inflammation and cellular stress responses. [663-674]

Receptor tyrosine kinases:

Single transmembrane domain with intrinsic tyrosine kinase activity
Ligand binding induces dimerization and autophosphorylation
Activation of downstream MAPK, PI3K, and PLCγ pathways
Examples: Insulin receptor, growth factor receptors

[675-684]

Cytokine receptors:

Associate with Janus kinases (JAKs) for signal transduction
JAK-STAT pathway activation modulates gene transcription
Relevant to anaesthetic effects on immune function and inflammation

[685-694]

Intracellular Receptor Mechanisms

Intracellular (nuclear) receptors act as ligand-activated transcription factors, modulating gene expression. Response latency reflects the time required for transcription and protein synthesis. [695-704]

Glucocorticoid receptor:

Cytoplasmic localization complexed with heat shock proteins (HSP90)
Ligand binding induces HSP dissociation and nuclear translocation
Homodimerization and binding to glucocorticoid response elements (GREs)
Transactivation (positive gene regulation) and transrepression (negative gene regulation)
Dexamethasone and methylprednisolone used for antiemetic and anti-inflammatory effects in anaesthesia

[705-718]

Drug Interactions at Receptor Level

Synergistic Interactions

Synergism occurs when combined drug effects exceed the sum of individual effects, often reflecting action at different points in a signaling pathway. [719-728]

Mechanisms of synergism:

Sequential pathway activation (e.g., propofol + fentanyl: GABA_A receptor potentiation + opioid receptor activation)
Complementary receptor actions (e.g., benzodiazepine + opioid: different mechanisms producing enhanced sedation)
Facilitated receptor activation (e.g., volatile anesthetics + NMBAs: increased acetylcholine receptor sensitivity)

[729-740]

Quantification of synergism using isobolographic analysis or response surface modeling allows optimization of drug combinations. [741-748]

Antagonistic Interactions

Antagonism occurs when one drug reduces another's effect through pharmacodynamic mechanisms: [749-758]

Pharmacological antagonism:

Competitive: Naloxone reversing opioid effects
Non-competitive: Irreversible α-blockers preventing catecholamine effects
Physiological: Insulin counteracting hyperglycemia from corticosteroids

[759-768]

Reverse agonism:

Flumazenil reversing benzodiazepine effects by competitive antagonism at GABA_A receptors

[769-776]

Tolerance and Tachyphylaxis

Tolerance: Reduced drug effect following repeated administration, requiring dose escalation to maintain response. Mechanisms include: [777-786]

Receptor downregulation (reduced receptor number)
Desensitization (reduced receptor responsiveness)
Upregulation of opposing systems (e.g., increased adenylyl cyclase after chronic opioid use)
Metabolic tolerance (increased clearance through enzyme induction)

Tachyphylaxis: Rapidly developing tolerance occurring within minutes to hours, often due to receptor desensitization or depletion of neurotransmitter stores. Examples include repeated ephedrine dosing (depletion of norepinephrine stores) and nitrate tolerance (sulfhydryl depletion). [787-798]

Mechanism	Time Course	Examples	Management
Pharmacokinetic tolerance (enzyme induction)	Days to weeks	Phenytoin, barbiturates	Dose adjustment based on levels
Receptor downregulation	Days to weeks	β-adrenergic receptors with chronic agonists	Drug rotation, receptor recovery period
Desensitization	Minutes to hours	β-adrenergic receptors with ephedrine, opioid receptors	Avoid continuous infusion, use intermittent dosing
Depletion	Minutes to hours	Ephedrine (NE depletion), nitrates (SH depletion)	Drug holidays, alternative agents

Table: Tolerance mechanisms and management strategies. [799-810]

Indigenous Health Considerations

Pharmacogenomic Variations in Aboriginal and Torres Strait Islander Peoples

Pharmacogenomics—the study of genetic variations affecting drug response—has significant implications for anaesthetic care in Indigenous populations. Aboriginal and Torres Strait Islander peoples exhibit genetic diversity that may influence drug metabolism, receptor sensitivity, and adverse effect profiles. [811-822]

Cytochrome P450 polymorphisms:

CYP2D6 metabolizes approximately 25% of clinically used drugs including many opioids (codeine, tramadol)
CYP2D6 poor metabolizer frequency varies among Indigenous populations; reduced codeine conversion to morphine may limit analgesic efficacy
CYP2C19 poor metabolizers exhibit reduced diazepam metabolism and prolonged sedation
CYP2C9 variants affect warfarin and phenytoin metabolism, potentially altering dosing requirements
Limited data specific to Aboriginal and Torres Strait Islander populations; population genetic studies are ongoing

[823-840]

Opioid receptor variations:

OPRM1 gene variants (A118G polymorphism) affect μ-opioid receptor function and opioid analgesic requirements
Studies in diverse populations show variable frequencies of functionally significant variants
Indigenous populations may exhibit different opioid sensitivity profiles affecting dosing requirements and adverse effect risks

[841-852]

Cholinesterase variants:

Butyrylcholinesterase (pseudocholinesterase) deficiency prolongs succinylcholine and mivacurium effects
Genetic variants affecting enzyme activity occur at varying frequencies across populations
Recognition of prolonged apnea following succinylcholine is essential in all populations

[853-862]

Cultural Factors Affecting Drug Response

Beyond genetic factors, cultural and social determinants influence pharmacodynamic responses in Indigenous patients: [863-874]

Stress and catecholamine responses:

Cultural safety and trust affect sympathetic nervous system activation
Anxiety related to unfamiliar environments or cultural disconnection may enhance sympathetic tone
Altered hemodynamic responses to anaesthetic drugs may occur in high-stress states
Catecholamine-mediated changes in hepatic blood flow may affect clearance of high-extraction drugs

[875-886]

Pain perception and expression:

Cultural variations in pain expression may affect opioid dosing assessments
Stoicism in some Indigenous cultures may lead to underreporting of pain and inadequate analgesia
Understanding cultural pain expression styles improves pain assessment and opioid titration
Pharmacodynamic response to opioids (analgesic effect) may be equivalent but pain reporting differs

[887-898]

Traditional medicine interactions:

Some traditional medicines may have pharmacodynamic effects interacting with anaesthetic drugs
Sedative traditional preparations may potentiate anaesthetic agents
Stimulant or sympathomimetic traditional medicines may antagonize sedative effects
Non-judgmental inquiry about traditional medicine use improves safety

[899-910]

Māori Pharmacogenomic and Cultural Considerations

Māori populations similarly exhibit genetic diversity relevant to anaesthetic pharmacodynamics. The Te Whare Tapa Whā model of health recognizes the interconnectedness of physical, mental, social, and spiritual dimensions, acknowledging that pharmacodynamic responses occur within this holistic framework. [911-922]

Genetic considerations:

CYP2C19 and CYP2D6 polymorphism frequencies in Māori populations may differ from European populations
Pharmacokinetic and pharmacodynamic studies specific to Māori populations are limited
Individualized dosing based on clinical response remains essential

[923-932]

Cultural safety in pharmacological management:

Whānau involvement in healthcare decisions affects patient stress levels and potentially drug responses
Manaakitanga (hospitality/care) principles apply to medication administration and explanation
Understanding that pharmacological interventions carry spiritual significance for some Māori patients
Communication about drug effects, side effects, and expectations must be culturally appropriate

[933-944]

Tiriti o Waitangi obligations:

The Treaty of Waitangi principles of partnership, protection, and participation apply to medication safety
Protection requires ensuring equivalent quality of anaesthetic care including pharmacological management
Addressing disparities in access to newer pharmacological agents (e.g., sugammadex availability)

[945-954]

Remote Practice Considerations

Aboriginal and Torres Strait Islander and Māori patients in remote settings face unique pharmacodynamic challenges: [955-966]

Delayed presentation effects:

Advanced disease pathology at presentation may alter receptor sensitivity and drug responses
Chronic hypoxia, malnutrition, or dehydration affects drug distribution and effect
Electrolyte abnormalities (common in chronic kidney disease) alter neuromuscular blocker pharmacodynamics

[967-978]

Limited reversal agent availability:

Remote facilities may lack sugammadex, requiring reliance on neostigmine for neuromuscular blockade reversal
Understanding pharmacodynamic differences between sugammadex and neostigmine essential
Neostigmine pharmacodynamics (muscarinic vs nicotinic effects) require careful management in resource-limited settings

[979-990]

Analgesic considerations:

Limited access to patient-controlled analgesia (PCA) and advanced multimodal regimens in remote settings
Regional anesthesia techniques may be preferred but require different pharmacodynamic considerations
Oral analgesic availability and patient adherence affect postoperative pain management

[991-1000]

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary MCQs extensively test pharmacodynamic principles through conceptual and calculation questions: [1001-1010]

Agonist-antagonist classification questions:

Distinguishing full agonists from partial agonists and antagonists
Identifying competitive vs non-competitive antagonism from concentration-response curves
Understanding inverse agonist mechanisms

Efficacy vs potency questions:

Interpreting concentration-response curves to identify relative efficacy and potency
Understanding that potency reflects EC50 position while efficacy reflects Emax height
Recognizing partial agonist characteristics (submaximal Emax, competitive antagonism of full agonists)

[1011-1024]

Receptor mechanism questions:

GABA_A receptor as target for propofol, benzodiazepines, etomidate, barbiturates
Opioid receptor types (μ, δ, κ) and their clinical effects
Nicotinic acetylcholine receptor as target for neuromuscular blockers
α2-adrenergic receptor as target for dexmedetomidine and clonidine

[1025-1036]

Signal transduction questions:

G-protein classifications (Gs, Gi, Gq) and their effector mechanisms
Second messenger systems (cAMP, IP3/DAG, Ca2+)
Ion channel mechanisms for ligand-gated receptors

[1037-1046]

Primary Viva Question Themes

Primary viva examinations systematically assess pharmacodynamic understanding through progressive questioning: [1047-1056]

Viva progression - Efficacy and potency:

"Define efficacy and potency, and explain the difference between these concepts"
"Given these two concentration-response curves [shown], which drug has higher potency? Which has higher efficacy?"
"Explain why buprenorphine has a ceiling effect on respiratory depression but morphine does not"
Expected answer: Buprenorphine is a partial agonist with lower intrinsic efficacy; once all receptors are occupied, no further effect is possible regardless of dose, creating a ceiling. Morphine is a full agonist with no ceiling on receptor activation. [1057-1070]

Viva progression - Competitive vs non-competitive antagonism:

"Explain the difference between competitive and non-competitive antagonism"
"Draw the expected concentration-response curves for an agonist in the presence of increasing concentrations of a competitive antagonist"
"How would the curves differ for a non-competitive antagonist?"
Expected answer: Competitive: parallel rightward shift, unchanged Emax, surmountable. Non-competitive: reduced Emax, may or may not shift EC50, insurmountable. [1071-1084]

Viva progression - Opioid receptor pharmacodynamics:

"Describe the opioid receptor types and their clinical effects"
"Why does naloxone reverse respiratory depression but also precipitate withdrawal in opioid-dependent patients?"
"Explain the concept of partial agonism using buprenorphine as an example"
Expected answer: μ-receptor mediates analgesia, euphoria, respiratory depression; κ-receptor mediates spinal analgesia, dysphoria; δ-receptor modulates μ effects. Naloxone is a competitive antagonist reversing all opioid effects including endogenous opioid tone in dependent patients. Buprenorphine high affinity but partial agonism explains ceiling effects and difficult reversal. [1085-1100]

Viva progression - GABA_A receptor:

"Describe the structure and function of the GABA_A receptor"
"How do benzodiazepines differ from propofol in their interaction with GABA_A receptors?"
"Why does flumazenil reverse benzodiazepine effects but not barbiturate or propofol effects?"
Expected answer: Pentameric ligand-gated chloride channel; benzodiazepines bind at α-γ interface as positive allosteric modulators requiring GABA presence; propofol binds at β subunit, can directly activate channel; flumazenil is competitive benzodiazepine antagonist, not active at propofol binding site. [1101-1114]

Calculation Questions

Pharmacodynamic calculations in the ANZCA Primary examination: [1115-1124]

Example calculation - pD2 and EC50: A drug has an EC50 of 2 × 10⁻⁶ M. Calculate the pD2 value.

Solution:

pD2 = -log(EC50 in M)
EC50 = 2 × 10⁻⁶ M = 0.000002 M
pD2 = -log(2 × 10⁻⁶) = -[log(2) + log(10⁻⁶)] = -[0.3 + (-6)] = -(-5.7) = 5.7

[1125-1140]

Example calculation - Schild analysis: In the presence of 10⁻⁷ M competitive antagonist, the EC50 of an agonist increases from 10⁻⁸ M to 10⁻⁷ M. Estimate the antagonist dissociation constant (Kb).

Solution:

Dose ratio = EC50(antagonist) / EC50(control) = 10⁻⁷ / 10⁻⁸ = 10
Schild equation: Dose ratio = 1 + [B]/Kb
10 = 1 + (10⁻⁷)/Kb
9 = 10⁻⁷/Kb
Kb = 10⁻⁷/9 ≈ 1.1 × 10⁻⁸ M

[1141-1156]

Assessment Content

SAQ Practice Question 1 (20 marks)

Question: Explain the concepts of efficacy and potency in pharmacodynamics. Compare morphine, fentanyl, and buprenorphine in terms of their efficacy and potency at μ-opioid receptors, and discuss the clinical implications of these differences.

Model Answer:

Efficacy and potency definitions: (4 marks)

Efficacy (intrinsic activity): Maximum biological response a drug can produce; reflects ability to activate receptor-effector system [1]
Potency: Drug concentration required to produce specified effect; typically expressed as EC50; reflects affinity and activation efficiency [1]
Efficacy is independent of concentration; potency describes position of concentration-response curve [1]
Two drugs may have different potencies but similar efficacy, or similar potency but different efficacy [1]

Morphine characteristics: (4 marks)

Full agonist at μ-opioid receptors with high intrinsic efficacy (α ≈ 1.0) [1]
EC50 for analgesia approximately 10-20 ng/mL (moderate potency among opioids) [1]
No ceiling effect on receptor activation; dose escalation produces increasing effects up to maximum physiological response [1]
Dose-dependent respiratory depression without ceiling (in absence of tolerance) [1]

Fentanyl characteristics: (4 marks)

Full agonist at μ-opioid receptors with high intrinsic efficacy similar to morphine [1]
EC50 approximately 0.2-0.5 ng/mL (50-100× more potent than morphine) [1]
High potency due to high receptor affinity (Kd ~1.2 nM) and excellent blood-brain barrier penetration [1]
Similar maximum response to morphine (equivalent efficacy) despite much lower concentrations [1]

Buprenorphine characteristics: (4 marks)

Partial agonist at μ-opioid receptors with intermediate intrinsic efficacy (α ≈ 0.5-0.6) [1]
High binding affinity (Kd ~0.2 nM) but lower efficacy than full agonists [1]
EC50 for analgesia approximately 0.2-0.5 ng/mL (potent binding) but submaximal effects [1]
Ceiling effect: Maximum response limited by intrinsic efficacy; cannot achieve same maximum as morphine or fentanyl regardless of dose [1]

Clinical implications: (4 marks)

Fentanyl preferred when rapid onset, high potency, and minimal histamine release desired; equipotent doses provide equivalent maximum analgesia to morphine [1]
Buprenorphine ceiling effect provides safety advantage: respiratory depression plateaus at ~30 mcg IV, limiting overdose risk; useful for chronic pain and opioid maintenance [1]
Buprenorphine high affinity and slow dissociation make reversal with naloxone difficult; may require higher naloxone doses or ventilation support [1]
Partial agonism means buprenorphine can precipitate withdrawal in opioid-dependent patients by displacing full agonists while providing submaximal activation [1]

Total: 20 marks

SAQ Practice Question 2 (20 marks)

Question: Describe the differences between competitive and non-competitive antagonism. Draw concentration-response curves showing the effects of increasing concentrations of each type of antagonist on an agonist's response. Explain the clinical relevance using specific examples from anaesthetic practice.

Model Answer:

Competitive antagonism description: (4 marks)

Competitive antagonists bind reversibly to same receptor site as agonist (orthosteric site) [1]
Do not activate receptor; block agonist access [1]
Antagonism is surmountable—increasing agonist concentration can overcome antagonism [1]
Parallel rightward shift of agonist concentration-response curve; unchanged Emax [1]

Non-competitive antagonism description: (4 marks)

Non-competitive antagonists reduce maximum response (Emax) of agonist [1]
May act via irreversible binding, allosteric modulation, or downstream pathway blockade [1]
Antagonism is insurmountable—increasing agonist cannot restore maximum response [1]
Depression of Emax; may or may not alter EC50 depending on mechanism [1]

Concentration-response curves - competitive: (3 marks)

Draw sigmoid curve for control agonist alone [1]
Show parallel rightward shifts with increasing antagonist concentrations (curves superimposable at high agonist concentrations) [1]
Label: unchanged Emax, dose-ratio increases, surmountable [1]

Concentration-response curves - non-competitive: (3 marks)

Draw sigmoid curve for control agonist alone [1]
Show progressive depression of Emax with increasing antagonist (curves reach lower plateau) [1]
Label: reduced Emax, may shift EC50, insurmountable [1]

Clinical examples - competitive: (3 marks)

Naloxone: Competitive opioid antagonist at all opioid receptor types; reverses respiratory depression; effects surmountable with high opioid doses [1]
Flumazenil: Competitive benzodiazepine antagonist at GABA_A receptor; reverses sedation; can be overcome by excess benzodiazepine [1]
Non-depolarizing neuromuscular blockers: Competitive antagonists at nicotinic acetylcholine receptors; blockade surmountable with high acetylcholine (neostigmine) [1]

Clinical examples - non-competitive: (3 marks)

Phenoxybenzamine: Irreversible α-adrenergic antagonist; covalent binding; cannot be overcome by catecholamines; used for pheochromocytoma preoperative management [1]
Ketamine: Non-competitive NMDA receptor antagonist; binds within channel; effects not surmountable with glutamate [1]
Organophosphates: Irreversible acetylcholinesterase inhibitors; covalent modification of enzyme; require reactivators or time for new enzyme synthesis [1]